{
    "clinical_study": {
        "@rank": "75607", 
        "arm_group": {
            "arm_group_label": "SERI\u00ae Surgical Scaffold", 
            "arm_group_type": "Experimental", 
            "description": "Women and men in need of soft tissue support undergoing ventral hernia repair."
        }, 
        "brief_summary": {
            "textblock": "Prospective, multi center, single arm, clinical study to obtain clinical experience with the\n      use of SERI\u00ae Surgical Scaffold for soft tissue support in ventral hernia repair."
        }, 
        "brief_title": "A SERI\u00ae Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ventral Hernia Repair", 
        "condition_browse": {
            "mesh_term": [
                "Hernia", 
                "Hernia, Ventral"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The following are requirements for entry into the study. The subject MUST:\n\n          1. Be \u2265 18 years of age\n\n          2. Be diagnosed with a ventral hernia as defined as:\n\n               1. Midline Ventral Hernia AND\n\n               2. Defect(s) MUST meet the following criteria:\n\n                    -  contained within an anatomical area of \u2264 150 cm2\n\n                    -  not be longer than 8cm in any direction\n\n                    -  size must have a total sum \u2264 64 cm2\n\n          3. Be eligible for retro-rectus placement of SERI\n\n          4. Have a BMI < 40\n\n        Exclusion Criteria:\n\n        The following are criteria for exclusion from participating in the study. The subject must\n        NOT:\n\n          1. Be > 70 years of age\n\n          2. Have prior occurrence of ventral hernia or parastomal hernia\n\n          3. Have a presence of a stoma or have a perforated bowel\n\n          4. Have any documented disease which is clinically known to impact wound healing,\n             including Chronic Obstructive Pulmonary Disease (COPD), and Congestive Heart Failure\n             (CHF), with the exception of controlled diabetes\n\n          5. Have documented history of diabetes with an A1C of \u2265 8 at time of pre-operative visit\n\n          6. Have documented autoimmune disease, an immune deficiency, or be on immunosuppressive\n             drugs with the exception of steroids for:\n\n               1. prophylactic one-time-use administered peri-operatively\n\n               2. inhaled general use\n\n               3. topical administration\n\n          7. Have documented collagen-vascular, connective tissue, bleeding disorders and/or on\n             anticoagulation therapy, with the exception of baby aspirin for one week prior to\n             SERI placement\n\n          8. Have documented cancer < 6 months prior to surgery or chemotherapy treatment < 6\n             months prior to surgery\n\n          9. Have documented history of abdominal radiation therapy or is expected to have\n             abdominal radiation therapy during the conduct of this study\n\n         10. Have documented history of liver disease and/or renal failure requiring dialysis\n\n         11. Have documented history of a previous wound infection at the surgical site or have an\n             active infection at the time of surgery\n\n         12. Have had prior surgery with synthetic and/or biologic mesh in the abdominal, chest or\n             pelvic area\n\n         13. Have documented allergy to silk\n\n         14. Have documented UTI at the time of surgery\n\n         15. Have smoked within 6 weeks of surgery and have a positive nicotine test at time of\n             preoperative visit\n\n         16. Have a concurrent procedure intra-operatively (with the exception of lysis of\n             abdominal adhesions)\n\n         17. Require intra-peritoneal or bridging placement of the soft tissue support device or\n             require component separation at time of surgery\n\n         18. Have surgical circumstances that are contraindicated for use of SERI\u2122 Surgical\n             Scaffold per the supplied package insert\n\n         19. Have a concomitant unrelated condition of abdominal/chest wall/skin that would\n             require a surgical intervention during the follow-up period\n\n         20. Have documented alcohol and/or substance abuse problem at time of pre-operative visit\n\n         21. Be pregnant, lactating, or if of childbearing potential, be unwilling to use\n             contraceptive methods and avoid pregnancy throughout the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981044", 
            "org_study_id": "SURE-007"
        }, 
        "intervention": {
            "arm_group_label": "SERI\u00ae Surgical Scaffold", 
            "description": "A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair", 
            "intervention_name": "Silk surgical mesh", 
            "intervention_type": "Device", 
            "other_name": "SERI\u00ae Surgical Scaffold"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Knoxville", 
                    "country": "United States", 
                    "state": "Tennessee"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Allergan Medical", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of hernia recurrence", 
            "safety_issue": "No", 
            "time_frame": "24 months postoperatively"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981044"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}